ORIC Pharmaceuticals, Inc.
ORIC
$5.07
-$0.24-4.52%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 12.82% | 12.55% | 15.05% | 13.19% | 6.68% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.51% | 28.99% | 32.80% | 33.84% | 27.92% |
| Operating Income | -28.51% | -28.99% | -32.80% | -33.84% | -27.92% |
| Income Before Tax | -30.56% | -26.96% | -28.60% | -19.68% | -13.19% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -30.56% | -26.96% | -28.60% | -19.68% | -13.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -30.56% | -26.96% | -28.60% | -19.68% | -13.19% |
| EBIT | -28.51% | -28.99% | -32.80% | -33.84% | -27.92% |
| EBITDA | -28.68% | -29.19% | -33.08% | -34.12% | -28.15% |
| EPS Basic | -3.87% | 7.15% | 9.42% | 19.16% | 17.37% |
| Normalized Basic EPS | -3.88% | 7.14% | 9.42% | 14.20% | 12.33% |
| EPS Diluted | -3.87% | 7.15% | 9.42% | 19.16% | 17.37% |
| Normalized Diluted EPS | -3.88% | 7.14% | 9.42% | 14.20% | 12.33% |
| Average Basic Shares Outstanding | 24.01% | 35.64% | 41.13% | 48.18% | 38.71% |
| Average Diluted Shares Outstanding | 24.01% | 35.64% | 41.13% | 48.18% | 38.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |